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Abstract
Aims: Protein aggregation and oxidative stress are both key pathogenic processes in Parkinson’s disease, although
the mechanism by which misfolded proteins induce oxidative stress and neuronal death remains unknown. In this
study, we describe how aggregation of alpha-synuclein (a-S) from its monomeric form to its soluble oligomeric state
results in aberrant free radical production and neuronal toxicity.Results:We first demonstrate excessive free radical
production in a human induced pluripotent stem-derived a-S triplication model at basal levels and on application of
picomolar doses of b-sheet-rich a-S oligomers. We probed the effects of different structural species of a-S in wild-
type rat neuronal cultures and show that both oligomeric and fibrillar forms of a-S are capable of generating free
radical production, but that only the oligomeric form results in reduction of endogenous glutathione and subsequent
neuronal toxicity. We dissected the mechanism of oligomer-induced free radical production and found that it was
interestingly independent of several known cellular enzymatic sources. Innovation: The oligomer-induced reactive
oxygen species (ROS) production was entirely dependent on the presence of free metal ions as addition of metal
chelators was able to block oligomer-induced ROS production and prevent oligomer-induced neuronal death.
Conclusion: Our findings further support the causative role of soluble amyloid oligomers in triggering neurode-
generation and shed light into the mechanisms by which these species cause neuronal damage, which, we show here,
can be amenable to modulation through the use of metal chelation. Antioxid. Redox Signal. 24, 376–391.
Introduction
Neurodegenerative diseases are becoming increas-ingly prevalent in the aging populations of the Western
world. These disorders, which include Parkinson’s disease
(PD), share a common feature of the accumulation of ab-
normally aggregated proteins in pathological inclusions
containing amyloid fibrils (13, 29). While the protein that is
deposited varies from one disease to another, the formation of
the inclusions occurs by a generic process of misfolding, by
which a normally soluble protein converts into fibrillar ag-
gregates via a series of oligomeric intermediates and ulti-
mately insoluble fibrils that are deposited in the brain.
Accumulating evidence suggests that soluble oligomeric
species generated during the formation of fibrils are the most
neurotoxic species linked with the development of these
types of diseases (8, 35, 38, 49, 53).
PD is characterized by the loss of midbrain dopaminergic
neurons and the presence of alpha-synuclein (a-S) neuronal
aggregated inclusions, known as Lewy bodies and Lewy
neurites. Rare forms of autosomal dominant familial PD can be
attributed solely to mutations in the SNCA gene or by genetic
duplication or triplication of the wild-type SNCA locus (46).
Duplication or triplication of the SNCA gene correlates with a
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younger age of disease onset and severity, suggesting that there
is a dose-dependent effect of the protein in disease causation.
These genetic and pathological data suggest that dysfunction/
misfolding of the a-S protein is a primary step in disease
pathogenesis and is sufficient to trigger the development of PD.
However, the underlying mechanism by which a-S aggregation
induces neuronal death during disease remains unknown.
Strong evidence exists to support a role of oxidative stress in
the pathogenesis of many neurodegenerative diseases, includ-
ing PD. There is clear evidence of oxidative damage to lipids,
proteins, and DNA (22) in postmortem PD brain. Basal lipid
peroxidation in substantia nigra is increased in PD, leading to
damage of intracellular components and apoptotic cell death,
both of which have been detected in autopsy tissue from the
brains of individuals with PD (43, 54). Animal models of PD
based on toxins (MPTP, rotenone, paraquat, and 6-OHDA)
induce oxidative stress and dopaminergic cell death and reca-
pitulate several of the motor and pathological aspects of PD.
Several of the genes known to cause familial PD also
impact on mitochondrial dysfunction and the generation of
reactive oxygen species (ROS) and susceptibility to oxidative
stress, including PINK1, parkin, DJ-1, SNCA, and LRRK2
(18, 24, 28). While a number of different processes are rec-
ognized to generate ROS in sporadic PD, namely mito-
chondrial dysfunction, dopamine metabolism, and iron and
calcium homeostasis, there remains a fundamental gap in our
understanding of how protein aggregation of a-S can impact
on the generation of ROS.
In this study, our aim has been to (i) study the role of ROS
production in a novel induced pluripotent stem cell (iPSC)-
derived neuronal model of PD bearing SNCA triplication, (ii)
identify which structural form of a-S is responsible for ROS
production, (iii) determine the mechanisms by which a-S in-
duces ROS generation, and (iv) investigate the relevance of a-S-
induced ROS production in disease. To address these objectives,
we have utilized iPSC neurons derived from an SNCA tripli-
cation patient (20) to assess the effects of long-term exposure to
increased levels of intracellular a-S and also two types of ex-
ogenously produced highly characterized monomeric, oligo-
meric, and fibrillar forms of a-S to identify the conformational
state of the protein primarily responsible for toxicity.
Results
Human iPSC-derived neurons with SNCA triplication
have high basal levels of ROS production
and oligomer-induced ROS production
To investigate the effects of long-term intracellular a-S
exposure, we initially assessed ROS production in iPSC-
derived neurons generated from an SNCA triplication patient
(two independent clones) and an unaffected first-degree
relative as a control (two independent clones) (20). We
employed a standard differentiation protocol to generate
iPSC-derived cortical neurons and confirmed the presence of
neurons using immunocytochemistry to the neuronal marker
bIII-tubulin (Fig. 1F). We further tested their functionality as
neurons by testing their calcium response to physiological
stimuli, ATP (which elicits a P2Y receptor-mediated calcium
response in astrocytes), and glutamate (which elicits a glu-
tamate receptor-mediated voltage-gated calcium channel
calcium signal in neurons) (representative traces of neuronal
response to glutamate are shown in Fig. 1G). Using this
protocol, we generate iPSC-derived neurons, of which 60–
70% display a calcium response to glutamate.
We utilized two independent ROS assessment methods:
first, we measured superoxide radical production as the rate
of increase in the ratio of dihydroethidium (HEt) fluorescence
between its oxidized and nonoxidized forms. In this method,
we measure the rate at which the DHE dye is oxidized (i.e.,
the slope of the increase in the fluorescence intensity of the
oxidized dye), which is proportional to the rate of superoxide
generation (30). Second, we assessed the rate of hydrogen
peroxide (H2O2) production using the Hyper-3 genetic
quantitative probe (5).
We assessed the basal rate of ROS production at day 50 in
culture (termed young neurons) and at day 80 in culture
(termed aged neurons). Using both methods, we observed a
significantly higher basal level of free radical production
in the aged triplication neurons compared with control at
day 80 in culture (normalized rate of superoxide production
158.3– 6.95 in SNCA triplication compared with control of
100%; n = 4 independent experiments across two clones,
n = 92 cells for control, n = 62 cells for triplication, p = 0.01;
Fig. 1A), the basal level of H2O2 was also significantly higher
(8.6 – 0.56 Hyper-3 ratio in SNCA triplication, n = 4 experi-
ments compared with 2.15 – 0.14, n = 4; in control; p < 0.001;
Fig. 1C–E). Importantly, young neurons at day 50 post-
differentiation did not show any difference in basal ROS
production between control and SNCA triplication (n = 3
experiments, 98%– 7.1% of control, Fig. 1A).
To determine if exposure to exogenous a-S has the ca-
pacity to increase the basal ROS rate, we added oligomeric a-
S to the cells generated using the method described in (14).
Using this method of aggregation, an oligomeric mixture can
be generated following 29 h of aggregation, at which time
point 0.8–1% of the mixture is oligomeric with a stable
compact beta-sheet structure, the rest of the preparation being
monomeric (referred to as oligomeric species). Exposure of
the aged control and triplication iPSC-derived neurons to
10 nM oligomeric species resulted in a significant increase in
free radical production in both assays. The rate of DHE
fluorescence ratio increased in control cells to 175% – 11.9%
(n= 4 experiments, p = 0.0062; rate of DHE fluorescence ra-
tio increased in SNCA triplication cells to 343% – 37.2%,
n = 4 experiments, p = 6.0E-05; Fig. 1A).
We utilized a second assay that is able to detect H2O2
through changes in the fluorescence of the genetic construct
Hyper-3. Following application of oligomers, the Hyper-3
ratio increased from a basal value of 2.15 – 0.14 for control
cells to 7.34– 0.39 and from a basal value of 8.6 – 0.56 for
triplication cells to 13.7 – 0.64 (Fig. 1C, E). Of note, the basal
Innovation
Our findings indicate that certain structural groups of
soluble oligomeric species formed during alpha-synuclein
amyloid fibril formation are especially damaging to heal-
thy primary neuronal cells and human induced pluripotent
stem cell-derived neurons through the induction of aber-
rant production of cytosolic ROS in a metal ion-dependent
manner that ultimately results in cell toxicity. We propose
that this linked process between amyloid aggregation, in-
duction of oxidative stress, and neuronal death is likely
central in the pathogenesis of Parkinson’s disease.
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FIG. 1. Oligomeric a-S induces ROS production in control and SNCA triplication neurons. (A) Basal and oligomeric
induced levels of ROS were assessed in young (50 days) and old (80 days) control and SNCA triplication differentiated neurons
using dihydroethidium. Old neurons were exposed to oligomers and the rate of ROS production was recorded. (B) Young
control and triplication neurons were exposed to 300 nM monomers, 300 nM oligomers (3 nM total oligomers), or 300 nM
fibrils, and ROS production was recorded and compared with basal ROS production levels. (C) Aged neurons (80 days) were
transfected with the cellular Hyper-3 construct, and H2O2 production in the presence of oligomers was recorded. Re-
presentative trace of H2O2 production rate in control aged neurons (black trace). A control pH construct (Hyper-CS) reported
no effect on intracellular pH (gray trace). (D) Representative trace of H2O2 production in triplication neurons exposed to
oligomers. (E) Quantification of basal and oligomer-induced H2O2 production in control and triplication neurons. (F) Im-
munocytochemistry for iPSC derived neurons for bIII-tubulin (green) and Hoechst (blue). (G) Cytosolic calcium response to
glutamate and ATP in iPSC derived neurons (representative traces). Bars indicate the incubation period of either oligomers or
H2O2. n‡ 4 experiments. Error bars indicate SEM; *p < 0.05; **p < 0.01; ***p < 0.001. a-S, alpha-synuclein (protein); H2O2,
hydrogen peroxide; ROS, reactive oxygen species; SNCA alpha-synuclein (gene). To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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level of ROS production was higher in the triplication neu-
rons (d80) compared with control, in keeping with the DHE
superoxide assay (Fig. 1D, E). Importantly, we performed
parallel experiments with a control Hyper construct (Hyper-
CS), which demonstrates altered fluorescence in response to
changes in pH. The negative results obtained using the con-
trol Hyper construct (Hyper-CS) indicate that these findings
are not a result of pH alterations (Fig. 1C, gray line). Addition
of H2O2 at the end of the experiment was used as a positive
control for the fluorescence signal from Hyper-3.
To determine whether the effect of the oligomeric a-S
species on human neurons was specifically due to the oligo-
meric species, we applied monomeric (300 nM), oligomeric
(300 nMmonomeric, 3 nM oligomeric), and fibrillar (300 nM)
a-S to the young day 50 control and triplication neurons
(Fig. 1B) and measured the increase in superoxide produc-
tion (the DHE fluorescence ratio). There was no significant
ROS induction by monomers (control+monomers 81%– 6.4%,
p= 0.065, triplication 103%– 8.4%, p= 0.773). Oligomers in-
duced ROS production (control 138%– 11.36%, p= 0.0018;
triplication 196%– 19.5%, p= 2.22183E-10). Fibrils induced
no significant ROS in control (124% – 14.5%, p = 0.065),
but induced ROS in triplication (136% – 11.8%, p = 0.002,
Fig. 1B).
Thus, a-S overexpression leads to an increase in basal ROS
production in human neurons when cultured for long periods
of time. Importantly, aggregated a-S (particularly in its
oligomeric form) is able to generate further ROS production
in neurons derived from iPSCs in both control and SNCA
triplication cells.
The ability of a-S to induce ROS is dependent
on its conformational state
In previous studies (14), we reported that exposure of rat
midbrain cultures to an aggregated solution of fluorescently la-
beled a-S containing a specific structural group of b-sheet-rich
oligomeric species can elicit a significant increase in cellular
ROS production. In the present work, we carried out analogous
experiments utilizing a newly described method of generating
and purifying a-S oligomers (11). Detailed biophysical charac-
terization of this method has confirmed that it is able to generate a
90% pure oligomer preparation whose structures have *30–
40% beta-sheet content and whose size varies from 10 to 40
protein molecules. They resemble the most highly compact and
stable species that are found to accumulate in a-S aggregation
methods characterized by single-molecule fluorescence studies
also used in this study. This method generated unlabeled popu-
lations of monomeric,b-sheet oligomeric (hereafter referred to as
enriched oligomeric), or fibrillar a-S species.
We observed that exposure of the neuronal cultures to
monomeric, oligomeric, or fibrillar a-S each produced a
different ROS response in the DHE assay (Fig. 2A–D).
Specifically, monomeric a-S produced a negligible change in
the rate of HEt ratio (with maximal values at 111.4% – 91%
of the basal rate for the addition of 40 nM; n = 94 cells; Fig.
2A). The enriched oligomers, however, produced a substan-
tially significant increase in the rate of ROS formation with
respect to the monomers, indicating that they have a profound
impact on cellular ROS production (n = 46 cells; 312– 18 of
basal; p < 0.001; Fig. 2B). Fibrils were able to elicit an ROS
response in neuronal cells, but this response is significantly
lower than that observed after exposure to the oligomeric
species (237.4% – 18% of basal rate; n = 32; p < 0.005;
Fig. 2C).
Comparable results were also obtained when analogous
experiments were carried out using the Hyper-3 probe for
H2O2 production (Fig. 2E–H). Specifically, exposure of cells
to monomeric a-S showed no significant increase in free
radical production (Fig. 2E, H; n= 18 cells; p > 0.05), while
exposure to both the oligomeric (by 5.9 – 0.5 ratio; n = 19
cells; p < 0.0001, Fig. 2F, H) and fibrillar species (by 1.9 – 0.3
ratio; Fig. 2G, H; n = 16 cells; p < 0.001) was able to induce
aberrant H2O2 production.
To ensure that the ROS production observed in the neuronal
cells is directly related to their exposure to oligomeric a-S
species, we conducted a dose–response assay. Figure 3A
demonstrates that exposing the neuronal cells to increasing
concentrations of enriched oligomeric a-S, from 10 pM to
40 nM (mass concentration), resulted in a stepwise increase in
cellular ROS production, indicating a direct correlation be-
tween the concentration of oligomeric protein and ROS pro-
duction. It is worth noting that addition of oligomer solutions at
a mass concentration of only 10 pM (which corresponds
to*0.4 pM of molecules of oligomers), that is, concentration
in terms of number of species (11), results in a significant
increase in cytosolic ROS production, which shows the degree
of specificity of this process and its relevance in the context of
disease. All subsequent experiments using the enriched olig-
omers were conducted with a final concentration of 40 nM
(mass concentration) a-S species unless otherwise stated.
a-S-induced ROS is independent of the major cellular
ROS production systems
The production of ROS in brain cells can be induced by
enzymatic or nonenzymatic mechanisms (28). Mitochondria
are considered to be one of the major sources of ROS pro-
duction in resting cells. Application of 40 nM labeled or en-
riched monomeric, oligomeric, or fibrillar a-S to primary
cocultures of neurons and astrocytes, loaded with the mito-
chondrial ROS indicator MitoSOX, had no significant effect
(Fig. 3C), indicating that the oligomer-induced ROS pro-
duction does not occur within the matrix of mitochondria.
Subsequent application of 1lM rotenone induced a signifi-
cant increase in the rate of MitoSOX ratio increase, con-
firming the ability of the MitoSOX probe fluorescence to
detect mitochondrial ROS (Fig. 3B). We also used a further
mitochondrial ROS indicator, MitoTracker red CM-H(2)X
ROS, which resulted in good localization of the fluorescent
indicator in the mitochondria of human iPSC-derived neu-
rons (Fig. 3D). In agreement with MitoSOX data on primary
neurons, monomeric, oligomeric, or fibrillar a-S did not
change the rate of ROS production in the matrix of mito-
chondria of human iPSC-derived neurons (Fig. 3Di).
To investigate the source of oligomer-induced ROS pro-
duction, we used a variety of inhibitors to block enzymes
known to be responsible for intracellular ROS production.
Inhibition of NADPH oxidase with 20lM of AEBSF or
0.5 lM DPI had no effect on enriched oligomeric a-S-
induced ROS production in neurons or astrocytes (Fig. 3F,
n = 99 cells for AEBSF; and n = 104 cells for DPI—ROS
levels were assessed for up to 30 min after a-S addition). Due
to the lack of selectivity of the NADPH oxidase inhibitors
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available, we utilized two different ones in these experi-
ments. Notably, DPI is a general flavoprotein inhibitor and
therefore also induces inhibition of endothelial nitric oxide
synthase, xanthine oxidase (XO), and certain proteins of the
mitochondrial electron transport chain. AEBSF, in addition
to its lower potency of NADPH oxidase inhibition, exerts
inhibitory effects on serine proteases. However, taken to-
gether, these nonselective effects tend to overestimate, rather
than underestimate, the role of NADPH oxidase (3).
Another important source of ROS in cells is the catabolism
of monoamines via monoamineoxidases, (MAO) A and B
(28). Selegiline is a selective and irreversible inhibitor of
MAO-B at lower concentrations, but is also able to inhibit
MAO-A at higher concentrations. Inhibition of this enzyme
by 20lM selegiline also had no effect on the rate of ROS
production induced by a-S in either neurons or astrocytes
(Fig. 3F, n= 177 [n = 66 neurons and 111 astrocytes] and 3E
shows representative traces). Inhibition of two further
FIG. 2. The ability of a-S
to induce ROS is dependent
on its structural conforma-
tion. The ability of each dif-
ferent a-S conformation to
induce ROS production in
WT rat neurons was assessed
using both labeled and unla-
beled preparations of mono-
mers (A), oligomers (B), and
fibrils (C, D) Quantification
of ROS production in WT rat
midbrain neurons upon expo-
sure to a-S species. WT rat
midbrain neurons were trans-
fected with the cellular
Hyper-3 construct and H2O2
production in the presence of
monomers (E), oligomers (F),
and fibrils (G) and recorded
(representative traces). (H)
Quantification of a-S-induced
H2O2 production rate in WT
rat neurons. Bars indicate the
incubation period of either a-S
species or H2O2. n= 3 experi-
ments. Error bars indicate
SEM; *p< 0.05; ***p< 0.001.
a-S, a-synuclein; WT, wild-
type.
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FIG. 3. a-S-induced ROS is independent of the major cellular ROS production systems. (A) Unlabeled enriched
oligomeric a-S was utilized to assess the dose-dependent effect of oligomers on ROS production. (B) Representative trace of
mitochondrial ROS production (MitoSOX) in WT rat neurons upon oligomeric a-S exposure; 1 lM rotenone induced a
significant increase of MitoSOX fluorescence. (C) Equivalent levels of labeled and unlabeled enriched a-S species were
assessed for their ability to induce mitochondrial ROS production in WT neurons using the mitochondrial ROS sensing dye,
MitoSOX. (D) Representative image of iPSC-derived neurons labeled with MitoTracker red CM-H(2)X ROS. (Di)
Representative traces of mitochondrial ROS production rate in the presence of monomeric, oligomeric, or fibrillar a-S in
iPSC-derived neurons. (E) Representative traces showing the marginal decrease in ROS levels by AEBSF pretreatment of
iPSC-derived neuron, (F) preincubation of WT neurons with inhibitors (DPI; Selegiline; Oxypurinol; NDGA) of the major
cellular sources of ROS failed to block ROS production induced by the unlabeled enriched oligomeric species. (G)
Quantification of ROS levels in control, a-S triplication, and AEBSF-treated a-S triplication neurons. Bars indicate the
incubation period of either a-S species or rotenone. n = 3 experiments. Scale bar= 10 lm; error bars indicate SEM.
**p < 0.01. AEBSF, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride; DPI, dibenziodolium chloride. To see this
illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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enzymes involved in cellular ROS production: XO (20lM
oxipurinol, a noncompetitive irreversible inhibitor of XO,
n = total 102 cells; 53 neurons and 49 astrocytes) and li-
pooxygenase (5 lM nordihydroguai-aretic acid, n = total 81
cells; 32 neurons and n = 49 astrocytes) also had no effect on
the oligomer a-S-induced ROS production (Fig. 3F). Not-
withstanding the recognized nonspecific effects of certain
inhibitors of cellular ROS production, these data suggest that
the ROS production, generated upon neuronal exposure to
oligomeric a-S, is independent of several of the known cel-
lular ROS generation mechanisms.
Interestingly, treatment of the aged human triplication
neurons (days 80–100) with AEBSF was able to partially
reduce the high basal levels of ROS production (from 151%
in triplication neurons –13.89, p = 0.011 compared with
control, to 127.9% in triplication neurons treated with
AEBSF –3.4, n = 13 neurons, p = 0.039), but could not com-
pletely block ROS production (Fig. 3G). These data strongly
suggest that NADPH oxidase is not involved in the mecha-
nism of ROS production induced specifically by oligomers,
but may contribute to the production of damaging ROS
species in human SNCA triplication neurons that have been
exposed to high intracellular levels of a-S for prolonged
periods of time. Under these circumstances, NADPH oxidase
may be activated via several different cellular mechanisms,
including alterations in calcium signaling (2, 37).
a-S oligomers induce ROS via a redox
metal ion-driven mechanism
It has been suggested that the toxicity of many aggregating
peptides could be related to their ability to bind transition
metal ions (9, 32). To determine if the a-S oligomers utilize
their ability to bind metal ions to generate ROS in our ex-
periments, we reassessed their ability to generate ROS in the
presence of several metal chelators. For these experiments,
we utilized the labeled oligomeric a-S characterized by
single-molecule fluorescence.
We applied several metal chelators (2lM desferrioxamine
[DFO]—iron chelator, 50lM D-pencillamine—copper che-
lator, and 50 lM clioquinol [CLQ]—highly lipophilic copper
and zinc chelator with moderate affinity for iron binding)
directly to the oligomers for 10 min before application of the
mixture to cells. In the presence of all the chelators, the
FIG. 4. a-S oligomers induce ROS via a redox metal ion-driven mechanism. (A) Preincubation of the oligomers with
different chelators, clioquinol, DFO, and D-PEN, for 10 min before addition to neurons resulted in a significant decrease in
the oligomer-induced ROS signal. (B) Preincubation of cells with the same chelators for 15 min, followed by application of
oligomers, also resulted in a significant reduction in the oligomer-induced ROS production. (C) Preincubation (15 min) of a-
S triplication iPSC neurons cells with the chelators, followed by application of oligomers, resulted in significant decrease in
oligomer-induced ROS production. Note that inhibitor of NADPH oxidase 20lM AEBSF had no effect on ROS production
induced by oligomers in iPSC neurons. (D) Basal ROS production in cells preincubated with different chelators (clioquinol,
DFO, and D-PEN) alone before the application of oligomers. n = 3 experiments. Error bars indicate SEM. *p< 0.05;
**p < 0.05; ***p < 0.001. D-PEN, 1,2-diphenyl-1,2-ethylenediamine; DFO, desferrioxamine; iPSC, induced pluripotent
stem cell.
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ability of the oligomers to induce ROS was significantly re-
duced (52.2%– 2.6% for CLQ, n= 62, p < 0.0001; 160.9%–
1.3% for DFO, n = 58, p= 0.0006; and 202.8 – 7.4, n = 55,
p = 0.0351 for D-PEN compared with oligomers alone,
275.3% – 28.6%, n = 75; Fig. 4A). Next, we preincubated
cells with the same chelators for 10 min before the applica-
tion of oligomers. Treatment of cells with the chelators alone
(before application of oligomers) did produce a variable in-
crease in the basal ROS (for CLQ 152% – 20.3%, n = 54,
p = 0.003, for DFO 200.7%– 18.1%; n = 58; p < 0.001, and
for D-PEN 127.2%– 8.9%; n = 87; p = 0.0023; Fig. 4D).
However, despite these changes in the basal ROS production,
pretreatment with the chelators significantly prevented ROS
production on application of oligomers (131.59%–6.2% for
CLQ, n=67, p=0.0028; 162.0%–2.8% for DFO, n=74,
p=0.0275; and not statistically significant for D-PEN-180.8%–
10.6%, n=54, p=0.1752; compared with oligomers without
pretreatment with chelators 232.5%–28.6%, n=87; Fig. 4B).
Importantly, the ability of metal chelator to reduce the
oligomer-induced ROS production was also tested on iPSC-
derived control and SNCA triplication neurons. For these
experiments, neurons were used at day 50 in culture so that
the basal levels of ROS were not significantly different.
Cells were preincubated for 10 min with vehicle, CLQ, DFO,
D-PEN, or AEBSF, and then 300 nM total a-S (3 nM oligo-
mers) was applied to the chamber. As confirmed in the aged
human neurons, the application of the oligomeric a-S to
young control or SNCA triplicated iPS neurons induced an
increase in the rate of ROS production. Oligomer-induced
ROS production in the iPSC-derived SNCA triplication
neurons (140% – 11.7%; n = 67 cells) could be reduced to
control levels by CLQ (105%– 4.6%; n=54 cells; p= 0.0014),
D-PEN (104%–4.7%; n= 87; p=0.007) or DFO (109%–
10.1%; n= 58 cells; p=0.019), but not by the inhibitor of
NADPH oxidase AEBSF (171%– 14.5%; p= 0.111; n=3 ex-
periments, Fig. 4C).
These combined data suggest that oligomeric a-S is able to
produce significant levels of superoxide radicals by a redox
metal-driven mechanism in neuronal model systems. More
specifically, copper and iron can be utilized by the oligomeric
species to produce ROS. Chelation of the metal ions before
application to cells and chelation of metal ions within cells
are both effective at preventing the oligomer-induced ROS
production.
FIG. 5. Exposure of neu-
ronal cultures to oligomeric
a-S reduces endogenousGSH
levels and increases lipid per-
oxidation. (A) Reduced GSH
levels of WT rat neurons after
incubation with the differenta-
S species for 48 h; the levels of
reduced GSH were assayed
using MCB. (B) Treatment of
neurons and astrocytes with the
metal chelators, TPEN, DFO,
or clioquinol, prevents the de-
crease in endogenous GSH
levels caused by the oligomer-
induced ROS production. (C)
Control and a-S triplication
cells were loaded with C11-
Bodipy and lipid oxidation
was recorded. Representative
trace of oligomeric-a-S-
induced lipid peroxidation in
control iPSC neurons. (D)
Representative traces of lipid
peroxidation in a-S triplication
cells preincubated with D-
PEN, DFO, clioquinol, or
solvent. (E) Quantification of
lipid peroxidation rate in a-S
triplication iPSC neurons pre-
incubated with chelators or
solvent. Bar indicates the in-
cubation period of oligomers.
n=3 experiments. Error bars
indicate SEM. **p<0.01;
***p<0.001. GSH, glutathi-
one; MCB, monochloro-
bimane; TPEN, N,N,N¢,N¢-
tetrakis(2-pyridylmethyl)ethyle
nediamine
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Exposure of neuronal cultures to oligomeric a-S
reduces endogenous glutathione levels and triggers
caspase-3/7 activation
ROS is normally produced in healthy cells during meta-
bolic processes and known to have an important role as sig-
naling molecules (25, 51). Oxidative stress is defined as a
misbalance in cell redox reactions, resulting in the increase of
ROS and decreased antioxidant defense systems. To identify
whether a-S-induced ROS production can induce oxidative
stress, we measured the level of the major antioxidant in
brain—glutathione (GSH).
We measured the cellular levels of GSH using mono-
chlorobimane (MCB) after 24 h of exposure to different
forms of a-S. Enriched oligomeric a-S (at a final concentra-
tion of 40 nM) significantly decreased the levels of reduced
GSH in neurons and astrocytes (to 76.8% of control in neu-
rons; n= 4 experiments; p< 0.001; and to 84.7% in astrocytes,
n = 4; p < 0.001; Fig. 5A), while the monomeric form had no
effect on the MCB fluorescence (n = 4). Importantly, al-
though fibrils produced an increase in ROS production, the
levels of ROS were insufficient to decrease the levels of re-
duced GSH and therefore to induce oxidative stress in the
neuronal cells (n = 4 experiments; Fig. 5A). Given our ob-
servations that metal chelators were able to inhibit oligomer-
induced ROS production, we further assessed the ability of
these chelators to rescue the reduction in endogenous levels
of reduced GSH. Strikingly, pretreatment of cells with any of
these chelators for 15 min before oligomeric exposure was
sufficient to prevent the reduction in GSH levels in both
neurons and astrocytes (Fig. 5B).
Activation of lipid peroxidation is another indication of
oxidative stress occurring within cells. Previously, we
showed that oligomeric a-S increased the rate of lipid per-
oxidation in primary neurons and astrocytes (4). In agreement
with these findings, we found that oligomeric a-S also stim-
ulated lipid peroxidation in control human iPSC-derived
neurons (Fig. 5C), as confirmed by an increase in the C11-
BODIPY (581/591) fluorescence ratio. We further studied the
basal rate of lipid peroxidation in the triplication neurons
using the increase in fluorescence ratio of C11-BODIPY in
the first 5 min following preincubation of cells with different
chelators. We have demonstrated that the oligomer-induced
lipid peroxidation in human iPSC-derived SNCA triplication
neurons could be significantly reduced by treatment of these
cells with CLQ (oligomer-treated triplication cell value
0.0436 – 0.002, n = 82 reduced to 0.01031 – 0.0043, n = 75),
DFO (reduced from 0.0436 – 0.002 to 0.00736– 0.001,
n = 84) and D-PEN (reduced from 0.0436– 0.002 to
0.0191 – 0.001, n = 64), with p-values for each chelator ver-
sus control p < 0.0001 (Fig. 5D, E).
FIG. 6. a-S oligomers
trigger oxidative stress-
induced caspase-3 activation
in neurons. WT rat midbrain
neurons were loaded with
NucView488 caspase-3 sub-
strate, which fluoresces green
upon caspase-3/7 activation.
Neurons were exposed to (A)
monomeric, (B) oligomeric,
and (D) fibrillar a-S, respec-
tively. (C) Representative im-
age of basal and oligomeric
a-S-induced caspase-3 acti-
vation. (E) Representative
traces demonstrating the inhi-
bition of oligomeric-induced
caspase-3 activation in cells
preincubated with 100lM
Trolox. (F) Quantification of
apoptosis (caspase-3 activa-
tion) in untreated, DFO, or
clioquinol-treated WT rat
neurons exposed to PBS or
oligomeric a-S. Bars indicate
the incubation period of either
a-S species or Trolox. Scale
bar= 50lm; n= 4 experi-
ments; error bars indicate
SEM. *p< 0.05; **p< 0.01.
To see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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To investigate if the levels of ROS production and oxi-
dative stress induced by oligomeric a-S could directly con-
tribute to cell death, we examined the effect of the different
forms of a-S on caspase-3/7 activation, one of the major
enzymes involved in the cell death cascade. We used the
NucView 488 caspase-3 substrate, which allows the visual-
ization of caspase-3/7 activation in real time. The increase in
the emitted 488 nm fluorescence in the nuclear region of cells
reflects the cleavage of the caspase-3 substrate (NucView) by
activated caspase-3/7 and the migration of the released
fluorescent dye to the nucleus. An increase in fluorescence as
indicated by the representative traces of individual cells in
Figure 6 demonstrates an increase in caspase-3/7 activation
and cleavage of the fluorescent substrate. Application of
oligomeric a-S induced a rapid activation of caspase-3/7 in
neurons (14.5% in 20 min of exposure; n = 4 experiments)
and astrocytes (11.6% in 20 min of exposure; n = 4 experi-
ments; Fig. 6B, C), whereas monomeric or fibrillar a-S failed
to activate caspase-3 (Fig. 6A, D).
To investigate whether a-S-induced caspase-3/7 activation
is directly mediated by ROS accumulation, we assessed
neuronal death by caspase-3/7 activation by treating cell
cultures with trolox (a water-soluble derivative of vitamin E),
an antioxidant agent commonly used to reduce oxidative
stress in cells. Pretreatment of the cells with trolox, before the
application of oligomeric a-S, prevented caspase-3/7 acti-
vation by oligomeric a-S (Fig. 6E; n = 3 experiments). This
suggests that the oligomeric a-S toxicity is driven mainly by
the generation and accumulation of ROS inside neuronal
cells. Given that our previous data suggested that treatment
with the metal chelators can alleviate both the aberrant ROS
production and reduction in reduced endogenous GSH levels,
we assessed whether treatment with the metal chelators could
also prevent caspase-3/7 activation. For these experiments,
single snap images were taken from five randomly selected
fields of view at baseline and at 30 min following application
of oligomers. Untreated cells showed a low level of basal
caspase-3/7 activation (2.1%– 1.4%, n= 315 cells; Fig. 6F),
which was significantly increased upon addition of the a-S
oligomers (15.4%– 4.4%; n = 316 cells; p = 0.017; Fig. 6F).
In contrast, pretreatment of the cells with either DFO
(2.2% – 0.86%; n = 598 cells; p= 0.014; Fig. 6F) or CLQ
(0.97% – 0.67%; n = 368 cells; p = 0.008; Fig. 6F) was suffi-
cient to protect against caspase-3 activation.
Discussion
a-S overexpression and misfolding are critical triggers in
the pathogenesis of PD. The interaction between a-S and
oxidative stress in PD models is considered to be complex
and bidirectional such that oxidative stress may promote the
aggregation of a-S, while at the same time the misfolding of
a-S is associated with increased ROS production. In this
study, we focused on the latter effect, that is, the ability of a-S
to intrinsically generate ROS, and the mechanism by which
this is achieved.
Previous studies have reported that overexpression of wild-
type or mutant a-S in vitro increases sensitivity to dopamine
toxicity (33, 48). Overexpression of wild-type and mutant a-S
can also induce ROS in neuroblastoma cells and enhance their
vulnerability to dopamine (33). Overexpression of wild-type
or mutant a-S in vivo models also results in increased sensi-
tivity to toxins inducing oxidative stress, including MPTP and
6-OHDA (42), while mice lacking a-S are resistant to MPTP
and mitochondrial toxins (15). It has been previously reported
that application of recombinant aggregated a-S (in the form of
preformed fibrils) induces an increase in cytosolic and mito-
chondrial ROS production (26). Concluding that both ex-
pression and aggregation of a-S may be fundamental to its
pathogenesis, we utilized models and tools to study both the
effect of long-term increase in endogenous a-S in human cells
and the structure-specific effects of a-S on mechanisms of
oxidative stress.
Patients bearing a triplication of the SNCA locus have early
onset, autosomal dominant PD associated with a-S inclusions
pathologically. iPSC-derived neurons from a patient bearing
the SNCA triplication recapitulate the doubling of a-S protein
found in patients and therefore provide an ideal model for
studying PD pathogenesis and its relationship with a-S pa-
thology (20). We report that human neurons with higher
levels of endogenous a-S for long periods of time in culture
exhibit high levels of ROS in the forms of superoxide and
H2O2. Thus, we confirm that increased expression of intra-
cellular a-S does indeed result in increased generation of
ROS at basal levels in a familial model of PD.
It is not yet clear whether the a-S-induced ROS production
is related to the level of expression of a-S or whether it is an
effect of protein misfolding and aggregation. It is technically
challenging to assess the different structural species of en-
dogenous a-S that exist within cells at high molecular reso-
lution. We therefore produced recombinant a-S and
generated samples of different structural forms of the protein
that correspond to different degrees of aggregation in the
protein. Of note, we employed two different types of aggre-
gation methods to generate the oligomeric a-S preparation. In
the first method, the protein was fluorescently labeled and
thus the oligomeric fraction of the preparation could be
characterized using singe-molecule fluorescence techniques
such as smFRET (14). Utilizing this method of oligomer
generation, we confirmed that the beta-sheet-rich compact
oligomers were the most highly damaging to human neurons
due to their unique ability to generate ROS. However, this
particular oligomer preparation consists of *1% oligomer
and therefore the presence of 99% monomeric a-S needs to be
considered in all experiments.
In this study, we also therefore utilized a new method of
oligomer generation that was able to form unlabeled prepa-
rations that were highly enriched in oligomers (90%).The
precise molecular structure of the intermediate species, the
oligomers, from this protocol was fully characterized using
biophysical techniques and found to resemble the most highly
compact and stable species that constitute the previous
oligomer preparations. Thus, we were able to compare di-
rectly the effects of pure samples of monomeric, soluble
oligomeric, and fibrillar a-S on wild-type neurons. We have
previously shown that all the a-S species and conformations
analyzed in this study are rapidly taken up by both neurons
and astrocytes (within 5–10 min), without significant varia-
tions between protein species (14), which allows us to di-
rectly correlate cellular readouts with the amounts of
different protein species added to the cells. Importantly, we
note that both oligomeric preparations were consistent in
their ability to generate high levels of ROS in primary neu-
rons and demonstrated the same mechanism of ROS
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production. Some differences between the potency in ROS
production were observed between the two preparations, and
this may be due to inherent structural differences between the
oligomers and also to the difficulty in using equivalent
oligomer concentrations for cellular experiments.
In this study, we demonstrate that a-S in its oligomeric
state is a highly potent inducer of superoxide production,
able to generate aberrant cytosolic ROS production even at
low picomolar concentrations of species. These effects were
demonstrated using different oligomer preparations, dif-
ferent ROS assays in two different cell models (primary
neuronal cocultures and human iPSC-derived cortical neu-
rons). Thus, we show that the misfolding of a-S into olig-
omers with particular structural characteristics is critical to
confer the toxic properties that can induce ROS production
(while other structural protein species are significantly less
efficient in inducing ROS production) (11). This process,
furthermore, is also associated with depletion of GSH, re-
flecting an inability of the antioxidant defenses to manage
the high levels of ROS produced (and thus leading to the
state of oxidative stress). High levels of oxidative stress
were further highlighted by the demonstration of elevated
lipid peroxidation induced by oligomeric a-S. Ultimately,
the a-S-induced oxidative stress is sufficient to result in
apoptosis and cell death. All together, these results suggest
that the formation and accumulation of certain structural
groups of soluble oligomeric forms of a-S are important
events in the pathogenesis of PD.
Several mechanisms have been proposed to account for a-
S-induced ROS production. These include (i) the interaction
of a-S protofibrils with vesicular membranes (52), resulting
in disruption of membrane integrity and leakage of cate-
cholamine and oxidized metabolites into the cytosol (41); (ii)
a-S-induced clustering of the dopamine transporter, resulting
in greater uptake of dopamine and higher cytosolic concen-
trations of dopamine (39); (iii) binding of a-S to the inner
mitochondrial membrane with impairment of complex 1 ac-
tivity and generation of ROS (12, 19); and (iv) activation
of cytosolic NADPH oxidase by a-S aggregates leading to
ROS production (26). We tested a range of cellular processes
that generate ROS and we found that the a-S oligomer-
induced ROS production was remarkably independent of
several of these processes, specifically mitochondrial matrix
ROS generation, catecholamine metabolism, and cytosolic
NADPH oxidase activity. We therefore concluded that the
oligomers were potentially able to generate ROS through a
nonenzymatic process that may be related to the specific
physicochemical and structural properties of certain oligo-
meric species.
Interestingly, incubation of the oligomers themselves with
metal chelators (of copper and iron) before application to
cells abolished their ability to generate ROS. This suggested
that the oligomers may interact with metal ions and that these
metal ions may be responsible for the ability of the oligomers
to induce ROS. Preincubation of the cells with chelators
before application of oligomers was also able to prevent the
oligomer-induced ROS generation and, furthermore, had
the effect of reversing the depletion of GSH and reversing
the apoptosis induced by oligomers. Thus, metal chelation
within cells and with oligomers was a potent strategy to
prevent oligomer-induced oxidative stress and oligomer-
induced cell death.
The nature of the synergistic interaction between metal
ions and oligomers remains unresolved, although we may
speculate whether it represents a direct or indirect interaction. It
is well established that a-S can interact with metal ions in a
nonspecific manner or with low-affinity or high-affinity binding
sites. These metal ion interactions modify the structure of a-S
and alter the propensity of it to aggregate into fibrils (45).
Monomeric a-S shows the highest affinity, in the nanomolar
range, for copper (6) and this metal is able to undergo reversible
redox cycling when bound to the protein (17). a-S also binds
iron and this was originally thought to be a low-affinity inter-
action, although recent studies have suggested that it can bind
iron in the low micromolar range (16). Purified recombinant a-
S has been reported to be able to reduce Fe3+ to Fe2+, opening
the possibility that a-S could act as a cellular iron-reducing
protein or ferrireductase (7). Interestingly, monomeric a-S, like
other proteins associated with neurodegeneration such as the
Ab peptide and the prion protein, has been reported to be able to
generate H2O2 and hydroxyl radicals in vitro in the presence of
small amounts of Fe2+, suggesting further that a-S can directly
generate ROS in a metal-dependent manner (47, 50). High
cellular levels of copper or iron result in cellular toxicity, and
the toxicity has been attributed to the redox activity of these
metal ions that can lead to the production of ROS through
Haber–Weiss or Fenton reactions (40).
It is of significant relevance that dysregulation of iron
homeostasis with resultant iron overload is well recognized in
PD and in several other synucleinopathies. Postmortem
analysis of PD brains reveals significantly higher levels of
iron in the substantia nigra (23) and within Lewy bodies (10).
Increased iron has also been demonstrated in the substantia
nigra of patients with PD using transcranial sonography and
T2*-weighted MRI. A putative iron regulatory element has
been reported in the 5¢ UTR of the mRNA encoding a-S,
suggesting that the regulation of the a-S protein production
may occur in response to changes in iron or redox events (27).
Of note, modulation of iron using chelator therapy has reduced
neuronal loss in the MPTP or 6-OHDA PD toxin models (34).
Indeed, desferiprone, a membrane-permeant bidentate chelator
that scavenges labile iron and confers protection against iron-
induced oxidative stress, has been shown to prevent iron de-
position in the substantia nigra and encouragingly slow disease
progression in early phase clinical trials (21). Our data suggest
that the toxic oligomeric forms of a-S are able to interact with
metal ions such as iron and copper and induce the production
of significant levels of ROS within cells, leading to metal-
dependent oxidant stress and cell toxicity. This work provides
a valid basis for the strategy of metal chelation as a neuro-
protective therapy in PD.
In summary, we have shown that production of ROS and
subsequent oxidative stress represents a major pathogenic
pathway in alpha-synucleinopathies. a-S in physiological
concentrations and in its monomeric state does not generate
production of ROS or toxicity. However, once the process of
aggregation begins, very small concentrations of toxic olig-
omeric species formed at the early stages of the self-assembly
process are sufficient to induce massive ROS production,
oxidative stress, and apoptosis. The mechanism by which the
toxic oligomer generates ROS is directly associated with
redox metal ions and we show that it can be prevented by the
chelation of free iron or copper. This work unravels the in-
teraction between protein misfolding, metal homeostasis, and
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oxidative stress and highlights the rational basis for a novel
therapeutic strategy in PD.
Materials and Methods
Preparation of the different a-S species samples
Human a-S was overexpressed and purified as a mono-
meric fraction from Escherichia coli as described previously
(31). Fibrils were prepared by incubating monomeric a-S at
70 lM (1 mg/ml) in phosphate-buffered saline (PBS) buffer
pH 7.4 (0.1 M ionic strength; 0.01% NaN3 was added to
prevent bacterial growth during aggregation) at 37C under
constant agitation (200 rpm) for 4–6 days. After this time,
the samples were centrifuged (10 min at 13.200 rpm) and
the fibrillar pellet was washed twice with PBS before being
resuspended into the appropriate volume of PBS to give
*100lM of fibrillar sample. Samples of a-S oligomers were
prepared by incubating monomeric protein at *800lM
(12 mg/ml) in PBS at 37C without agitation for 18–22 h. To
get this high concentration of protein, a solution of mono-
meric a-S in miliQ water was lyophilized and typically 6 mg
of lyophilized a-S was resuspended in 500 ll of PBS buffer.
The resulting solution was passed through a filter device with
a 0.22 lM cutoff to remove any particles of dust and/or large
protein aggregates that could have been formed during the
lyophilization process. After incubating this solution at 37C,
without agitation, for 18–22 h, most of the protein remains
monomeric, but a fraction of*5% of the protein is in the form
of aggregates. These aggregates are still soluble after ultra-
centrifugation at 90,000 rpm for 1 h. To isolate these aggre-
gates from the monomeric protein, a series of filtering devices
with a 100 kDa cutoff were used so that the monomeric protein
passed through the membrane, while oligomeric species bigger
than 100 kDa remained at the top of the filter.
Fluorescently labeled oligomers were generated by the
same procedure by mixing a sample of 400 lM of Alexa
Fluor-488 (AF488)-labeled protein with one of 400lM
Alexa Fluor-647 (AF647)-labeled protein to give a solution
with a total protein concentration of 800lM in PBS. The
A90C mutant variant of a-S was expressed in, and purified
from, E. coli as described previously (31) and labeled with
either maleimide-modified AF488 or AF647 dyes (Invitro-
gen) via the cysteine thiol moiety (at labeling efficiencies of
98% – 3% for both cases as estimated by mass spectrometry).
The labeled protein was purified from the excess of free dye
by a P10 desalting column with Sephadex G25 matrix (GE
Healthcare), divided into aliquots, flash-frozen, and lyophi-
lized; the lyophilized protein was stored at -20C.
For the single-molecule FRET analysis of the fluorescently
labeled oligomers, a 2 ll aliquot was diluted 105-fold by se-
rial dilution with 0.022lm filtered Tris 25 mM, pH 7.4, 0.1 M
NaCl. Glass slides were incubated for 1 h with bovine serum
albumin (BSA) at 1 mg/ml to prevent a-S species from ad-
sorbing to the surface, as we have recently shown (14). Im-
mediately after removal of the BSA solution, 500 ll of
diluted sample was placed on the slide for analysis.
Human control and triplication iPSC culture
and differentiation
iPSCs were maintained on irradiated SNL feeders (avail-
able from European Collection of Cell Cultures, ECACC)
and supplemented with hESC medium (Knockout DMEM,
20% KSR, 2 mM L-glutamine, 1· nonessential amino acids,
50lM 2-mercaptoethanol, 50 U/ml penicillin, 50lg/ml
streptomycin [all from Invitrogen], and 20 ng/ml FGF2 [Pe-
protech]). iPSCs were then subjected to a dual SMAD inhi-
bition protocol for neuronal differentiation. To commence
neuronal differentiation, iPSC cultures were dissociated with
Accutase (Invitrogen) to generate single-cell suspensions,
then differentially plated on gelatine-coated plasticware
for 1 h in hESC medium in the presence of ROCK inhibi-
tor (Y27632; Ascent) to remove SNL feeders. Nonattached
cells were resuspended in MEF-CM (R&D Systems) with
10 ng/ml FGF2 (Peptrotech) and plated on hESC-grade Ma-
trigel (BD) at a density of 50,000 cells/cm2 and allowed to
propagate in self-renewal conditions for 72 h or until 90%
confluent, whereupon media were changed to KSR medium
containing 100 nM LDN-193189 (Stemgent) and 10 lM
SB431542 (Tocris) added daily. After 5 days, KSR medium
containing 100 nM LDN-193189 was cross-tapered with
N2B27 medium (Stem Cells) containing 100 nM LDN-193189
over 7 days (75% KSR and 25% N2B27 first day, 50% of each
third day, then 25% KSR and 75% N2B27 fifth day). At day
11, cells were dissociated with Accutase (Invitrogen) and re-
plated at a 1:2 ratio on plasticware coated with 5lg/ml laminin
and 5lg/ml fibronectin (both from Sigma) in N2B27 media
supplemented with 20 ng/ml BDNF and 10 ng/ml GDNF (both
from Peprotech). Thereafter, media were half changed on al-
ternate days and cells were maintained in culture for*80 days
before experiments were carried out.
The generation of cortical neurons using this protocol was
tested using immunocytochemistry for neuronal markers.
Control and SNCA triplication iPSC-derived neurons grow-
ing on iBidi slides were fixed in 4% paraformaldehyde for
20 min at room temperature, washed in PBS once, and per-
meabilized with 0.2% Triton-100 for 20 min at room tem-
perature. The cells were then blocked in PBS containing 5%
BSA for 1 h at room temperature, followed by overnight in-
cubation with primary antibodies overnight at 4C. Mouse
monoclonal anti-beta-III-tubulin antibody (Abcam ab7751;
1:500 dilution) was used for labeling the neuronal population.
Alexa Fluor-488-conjugated anti-mouse secondary antibody
was used for visualization. Cells were imaged using a Zeiss
710 CLSM confocal system.
Differentiation into cortical neurons was further validated
by testing the calcium response to physiological neuronal
stimuli. Control and SNCA triplication iPSC-derived neuronal
cultures were loaded for 30 min at room temperature with
5lM fura-2 AM and 0.005% Pluronic in an HEPES-buffered
salt solution (HBSS) comprising (mM) 156 NaCl, 3 KCl,
2MgSO4, 1.25 KH2PO4, 2 CaCl2, 10 glucose, and 10 HEPES,
pH adjusted to 7.35 with NaOH; 100lM ATP was applied to
cells to stimulate a calcium signal in astrocytes, and this was
followed by 5lM glutamate to stimulate a calcium signal in
neurons. Fluorescence measurements were obtained on an
epifluorescence inverted microscope equipped with a 203
fluorite objective. [Ca2+]c was monitored in single cells using
excitation light provided by a Xenon arc lamp, the beam
passing the monochromator at 340, 360, and 380 nm (Cairn
Research). Emitted fluorescence light was reflected through a
515 nm long-pass filter to a cooled CCD camera (Retiga; QI-
maging) and digitized to 12-bit resolution. All imaging data
were collected and analyzed using software from Andor.
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Primary neuronal culture preparation
Mixed neuronal midbrain cultures were prepared from
Sprague-Dawley rat pups 3 days postpartum (UCL breeding
colony). Subjects were culled via schedule-1 decapitation
and the midbrain was dissected into ice-cold HEPES-
buffered salt solution (Ca2+, Mg2+-free; Gibco-Invitrogen).
The tissue was minced and trypsinized (0.25% for 15 min at
37C), triturated, and plated on poly-D-lysine-coated 22-mm
coverslips and cultured in neurobasal A medium (Gibco-
Invitrogen) supplemented with B-27 (Gibco-Invitrogen) and
2 mM glutamax. Cultures were maintained at 37C in a hu-
midified atmosphere of 5% CO2 and 95% air, fed once a
week, and maintained for a minimum of 14 days before ex-
perimental use. Neurons were easily distinguishable from
glia: they appeared phase bright, had smooth rounded somata
and distinct processes, and lay just above the focal plane of
the glial layer. Cells were used at 14–16 days in vitro. Animal
husbandry and experimental procedures were performed in
full compliance with the United Kingdom Animal (Scientific
Procedures) Act of 1986.
ROS assessments
Fluorescence measurements were obtained on an epi-
fluorescence inverted microscope equipped with a 20· fluo-
rite objective. For HEt and MitoSOX measurements, ratios
of the oxidized to reduced forms of the dye were measured:
excitation at 540 nm and emission recorded above 560 nm
were used to quantify the oxidized form (ethidium),
whereas excitation at 360 nm and emission collected from
405 to 470 were used for the reduced form (hydroethidium).
All data reported in this study were obtained from at least
five coverslips and two to three different cell and sample
preparations.
For measurement of mitochondrial ROS production, cells
were preincubated with MitoSOX (5 lM; Molecular Probes)
or MitoTracker Red CM-H(2)XROS for 10 min at room
temperature. For measurement of cytosolic ROS production,
HEt (2 lM) was present in the solution during the experiment.
No preincubation (loading) was used for HEt to limit the
intracellular accumulation of oxidized products. MitoTracker
Red CM-H(2)XROS measurements were produced using
560 nm excitation and emission above 580 nm.
For the intracellular H2O2 assessments using the Hyper
constructs, primary rat neurons and human iPSCs were
transfected with the Hyper-3 construct or the Hyper-CS
control pH probe using Effectene according to the manu-
facturers’ instructions (QIAGEN). Importantly, due to the
toxicity of the Effectene reagent in combination with Neu-
robasal A media, cells were exposed to the transfection
complexes for an hour before the media were replaced with
normal Neurobasal A growth medium. Cells were then left to
express the constructs for 48 h before experiments were
performed. Hyper-CS/3 were excited at 488 and 405 nm and
emission was set to 510–540 nm and values were expressed
as 488/405 ratio (5, 44).
The rate of lipid peroxidation was measured using con-
focal microscopy. Confocal images were obtained with a
Zeiss 710 LSM with an integrated META detection system.
To assess lipid peroxidation, C11-BODIPY (581/591, 2 lM;
Molecular probes) was excited using the 488 and 543 nm
laser line and fluorescence measured using a band-pass filter
from 505 to 550 nm and 560 nm long-pass filter (40· ob-
jective). Illumination intensity was kept to a minimum (at
0.1–0.2% of laser output) to avoid phototoxicity and the
pinhole set to give an optical slice of *2 lm. Addition of a
bright-field image allowed separation between neurons and
glia that are visibly different and are situated on different
focal planes. Data were acquired and analyzed using
ZEN2009 software.
GSH assessments
Neuronal cultures were incubated with 50lM MCB (Mo-
lecular Probes, Invitrogen) for 40 min in HEPES-buffered salt
solution before imaging (1, 36). Cells were then washed with
HEPES-buffered salt solution and images of the fluorescence
of the MCB-GSH were acquired using a Zeiss UV-vis 510
CLSM with excitation at 351 nm and emission at 435–485 nm.
Caspase-3 assays
Neuronal cultures were incubated with 5 ll of NucView
488 reagent (Biotium) per ml of culture media for 20 min at
37C, 5% CO2. Cells were then imaged using a Zeiss 710
LSM confocal microscope equipped with an META detec-
tion system and an ·40 oil immersion objective.
For measurements of caspase-3/7 activation, cells were
loaded for 15 min at room temperature with 10 lM NucView
488 caspase-3 substrate (Biotium) in HBSS. NucView 488 is
a novel class of enzyme substrates for real-time detection of
caspase-3/7 activity in live cells. The substrate can rapidly
cross the cell membrane to enter the cell cytoplasm, where it
is cleaved by caspase-3/7 to release the high-affinity DNA
dye. The released DNA dye migrates to the cell nucleus to
stain the nucleus bright green.
Confocal images were obtained using a Zeiss 710 confocal
laser scanning microscope and a 40· oil immersion objective.
The 488 nm argon laser was used to excite NucView 488
fluorescence, which was measured using a band-pass filter
from 510 and 560 nm.
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Abbreviations Used
6-OHDA¼ 6-hydroxydopamine
AEBSF¼ 4-(2-aminoethyl)benzenesulfonyl
fluoride hydrochloride
BSA¼ bovine serum albumin
CLQ ¼ clioquinol
DFO ¼ desferrioxamine
DHE ¼ dihydroethidium
D-PEN ¼ 1,2-diphenyl-1,2-ethylenediamine
DPI ¼ dibenziodolium chloride
GSH ¼ glutathione
H2O2 ¼ hydrogen peroxide
HBSS ¼ HEPES-buffered salt solution
hESC ¼ human embryonic stem cells
HEt ¼ dihydroethidium
iPSC ¼ induced pluripotent stem cell
KSR ¼ knockout serum replacement
MAO ¼ monoamineoxidase
MCB ¼ monochlorobimane
MPTP ¼ mitochondrial permeability
transition pore
NDGA ¼ nordihydroguaiaretic acid
PBS ¼ phosphate-buffered saline
PD ¼ Parkinson’s disease
ROS ¼ reactive oxygen species
SNCA ¼ alpha-synuclein
SNL ¼ immortalized cell line derived from mouse
fibroblast cells
TPEN ¼ N,N,N¢,N¢-tetrakis(2-pyr-
idylmethyl)ethylenediamine
XO ¼ xanthine oxidase
WT ¼ wild-type
a-S ¼ alpha-synuclein
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